Access Bio Inc Total Assets
Access Bio Inc total assets. Based on the latest financial reports, Access Bio Inc (950130) holds total assets worth ₩667.01 Billion KRW (≈ $452.02 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 950130 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Access Bio Inc (2012–2024)
Total assets of Access Bio Inc from 2012 to 2024. This chart illustrates how Access Bio Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Access Bio Inc for real-time trading data and today's change.
Access Bio Inc - Asset Composition Analysis
Access Bio Inc Total Assets Breakdown (December 2024)
Access Bio Inc total assets breakdown as of December 2024. Access Bio Inc's total assets of ₩667.01 Billion consist of 67.5% current assets and 32.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 46.2% |
| Accounts Receivable | ₩5.27 Million | 1.1% |
| Inventory | ₩15.96 Million | 3.2% |
| Property, Plant & Equipment | ₩93.32 Million | 18.5% |
| Intangible Assets | ₩431.01K | 0.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Access Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Access Bio Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Access Bio Inc's current assets represent 67.5% of total assets in 2024, an increase from 58.5% in 2012.
- Cash Position: Cash and equivalents constituted 46.2% of total assets in 2024, up from 3.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is property, plant & equipment at 18.5% of total assets.
Access Bio Inc Competitors by Total Assets
Key competitors of Access Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonza Group AG
SW:LONN
|
Switzerland | CHF18.26 Billion |
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.42 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
Access Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.67 | 11.32 | 1.06 |
| Quick Ratio | 15.02 | 10.59 | 0.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩415.34 Billion | ₩400.86 Billion | ₩2.18 Billion |
Access Bio Inc - Advanced Valuation Insights
This section examines the relationship between Access Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.31 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -99.9% |
| Total Assets | ₩503.98 Million |
| Market Capitalization | $45.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Access Bio Inc's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Access Bio Inc's assets decreased by 99.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Access Bio Inc (2012–2024)
The table below shows the annual total assets of Access Bio Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩503.98 Million ≈ $341.54K |
-99.93% |
| 2023-12-31 | ₩691.14 Billion ≈ $468.37 Million |
+98815.56% |
| 2022-12-31 | ₩698.71 Million ≈ $473.51K |
+87.40% |
| 2021-12-31 | ₩372.85 Million ≈ $252.67K |
+138.36% |
| 2020-12-31 | ₩156.42 Million ≈ $106.00K |
+159.72% |
| 2019-12-31 | ₩60.23 Million ≈ $40.81K |
-29.00% |
| 2018-12-31 | ₩84.82 Million ≈ $57.48K |
-2.67% |
| 2017-12-31 | ₩87.15 Million ≈ $59.06K |
-4.46% |
| 2016-12-31 | ₩91.22 Million ≈ $61.82K |
-99.89% |
| 2015-12-31 | ₩81.12 Billion ≈ $54.97 Million |
+2.77% |
| 2014-12-31 | ₩78.93 Billion ≈ $53.49 Million |
+33.36% |
| 2013-12-31 | ₩59.19 Billion ≈ $40.11 Million |
+103.46% |
| 2012-12-31 | ₩29.09 Billion ≈ $19.71 Million |
-- |
About Access Bio Inc
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities wi… Read more